EHA Guidelines on Management of Antithrombotic

Treatments in Thrombocytopenic Patients With

Cancer

Aymen Omer
Definition:
 What are the causes of, thrombocytopenia in cancer
patients?
1) BM infiltration by cancer cells
2) Chemotherapy
 What are the medications should be used with cautions in
thrombocytopenic cancer patients?
1) Anticoagulant.
2) Antiplatelet.
3) Fibrinolytic agents.
 Why do we give prophylaxis cancer-associated
thrombosis?
1) cardioembolic prevention: AF
2) thrombosis even in case of thrombocytopenia.
 Cancer patients remain at risk of venous and arterial thrombosis in
spite of TP, since mild-to-moderate TP does not protect against
arterial or venous thrombosis and is associated with more adverse
outcomes. General risk factors (age, diabetes, obesity, tobacco use)
and specific mechanisms (inflammation, hypercoagulability) are
shared between cancer and thrombosis.
 Moreover, some chemotherapeutic agents may induce endothelial
dysfunction. Finally, during the post-nadir, recovery phase,
chemotherapy-induced TP is associated with an increased output of
immature platelets, known to be hyper-reactive and associated with
more major arterial events in nononcological patients. Thus, TP
should be interpreted in its clinical, oncological, and
pharmacological context.